

Background

Interferon-gamma (IFN- γ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature equine IFN- γ exists as a noncovalently linked homodimer of 20 - 25 kDa variably glycosylated subunits (3, 4). It shares 73% - 82% amino acid sequence identity with bovine, canine, feline, and porcine IFN- γ and 42% - 64% with cotton rat, human, mouse, rat, and rhesus IFN- γ . IFN- γ dimers bind to IFN- γ RI (alpha subunits) which then interact with IFN- γ RII (beta subunits) to form the functional receptor complex of two α and two β subunits. Inclusion of IFN- γ RII increases the binding affinity for ligand and the efficiency of signal transduction (5, 6). IFN- γ is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (7). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (7, 8). In addition, IFN- γ functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (9, 10). The pleiotropic effects of IFN- γ contribute to the development of multiple aspects of atherosclerosis (8).

References:

1. Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. **20**:97.
2. Pestka, S. *et al.* (2004) Immunol. Rev. **202**:8.
3. Grunig, G. *et al.* (1994) Immunogenetics **39**:448.
4. Curran, J.A. *et al.* (1994) DNA Seq. **4**:405.
5. Marsters, S.A. *et al.* (1995) Proc. Natl. Acad. Sci. **92**:5401.
6. Krause, C.D. *et al.* (2000) J. Biol. Chem. **275**:22995.
7. Schroder, K. *et al.* (2004) J. Leukoc. Biol. **75**:163.
8. McLaren, J.E. and D.P. Ramji (2009) Cytokine Growth Factor Rev. **20**:125.
9. Muhl, H. and J. Pfeilschifter (2003) Int. Immunopharmacol. **3**:1247.
10. Kelchtermans, H. *et al.* (2008) Trends Immunol. **29**:479.

Description

Source	<i>E. coli</i> -derived Ala25 - Gln166 Accession # BAA05876
N-terminal Sequence Analysis	Ala25
Predicted Molecular Mass	16.7 kDa

Specifications

Activity	Measured in an anti-viral assay using L-929 mouse fibrosarcoma cells infected with encephalomyocarditis (EMC) virus. Vogel, S.N. <i>et al.</i> (1982) Infect. Immunol. 38 :681. The ED ₅₀ for this effect is typically 2 - 8 ng/mL.
Endotoxin Level	<1.0 EU per 1 μ g of the protein by the LAL method.
Purity	>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS and NaCl with BSA as a carrier protein. See Certificate of Analysis for details.

Preparation and Storage

Reconstitution	Reconstitute at 25 μ g/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

11/19/2009

FOR RESEARCH USE ONLY.
NOT FOR USE IN HUMANS.